Drug intelligence / Profile preview

sodium morrhuate

Development stage: Phase 2
Modality: Small Molecules
Administration: Intravenous

Overview

Sodium morrhuate is a sclerosing agent composed of the sodium salts of saturated and unsaturated fatty acids derived from cod liver oil. It is used primarily for the treatment of small, uncomplicated varicose veins of the lower extremities. The drug acts by causing inflammation and subsequent damage to the intima (inner lining) of veins, leading to thrombus formation and eventual obliteration (closure) of the vein through fibrosis. Its mechanism involves direct cytotoxic effects on endothelial cells, red blood cells, and granulocytes at the site of injection, resulting in sclerosis rather than induction via plasma coagulation pathways. Sodium morrhuate has been used as a sclerosant since at least 1933[1][2][5][6][7][8].

Other names: sodium salts of the fatty acids in cod liver oil

Beyond the preview

Go deeper on sodium morrhuate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium morrhuate.

Explore the full profile